Using a new bottom-up approach for rational drug design, researchers at Rice University and The University of Texas M. D. Anderson Cancer Center have re-engineered the powerful anticancer drug imatinib – best known by its brand name Gleevec – to more specifically target one type of cancer while potentially curbing a rare life-threatening cardiotoxic side effect.
